Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen joined Proactive's Stephen Gunnion with encouraging outcomes from latest cancer treatment trials.
The pharmaceutical company has observed a significant response rate in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Remarkably, within the MDS group, the response rate hit 100%.
These results come from the company's research combining immunotherapy and chemotherapy.
This combination has shown effectiveness even in patients who were previously refractory to standard treatments, including BCL-2 inhibitors, macro Lima, and sundry map. The treatment aims to eradicate cancer cells, leading to complete remission and has demonstrated a profound change in patient profiles.
Dr Jalkanen highlighted that this is part of the second phase of the ongoing 'next map' trial, which involves a careful dose escalation process under FDA guidelines. The trial aims to finalize dosing levels this year, moving towards pivotal phases and regulatory approval.
With a response rate anticipated to be significantly higher than current treatments, the company is eyeing a potential breakthrough in treating aggressive myeloid malignancies, which have short life expectancies.
The company plans to submit additional data from 32 patients to determine the final dose levels, leading to a decisive pivotal trial. With hopes of gaining FDA approval, Faron Pharmaceuticals is positioned to make a substantial impact on cancer treatment, potentially bringing new hope to patients with limited options.